Clinical Trial Update: Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing immunogenicity of GSK's 10-valent pneumococcal conjugate vaccine has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections
• Streptococcus Pneumoniae Infections

Drugs mentioned

• 10-valent pneumococcal conjugate vaccine (pneumococcal conjugate vaccine (10-valent))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Streptococcal, Streptococcus Pneumoniae Vaccines | Phase 3 | Status: COMPLETED